ABSTRACT
Background Although rapid screening for and diagnosis of COVID-19 are still urgently needed, most current testing methods are either long, costly, and/or poorly specific. The objective of the present study was to determine whether or not artificial-intelligence-enhanced real-time MS breath analysis is a reliable, safe, rapid means of screening ambulatory patients for COVID-19.
Methods In two prospective, open, interventional studies in a single university hospital, we used real-time, proton transfer reaction time-of-flight mass spectrometry to perform a metabolomic analysis of exhaled breath from adults requiring screening for COVID-19. Artificial intelligence and machine learning techniques were used to build mathematical models based on breath analysis data either alone or combined with patient metadata.
Results We obtained breath samples from 173 participants, of whom 67 had proven COVID-19. After using machine learning algorithms to process breath analysis data and further enhancing the model using patient metadata, our method was able to differentiate between COVID-19-positive and -negative participants with a sensitivity of 98%, a specificity of 74%, a negative predictive value of 98%, a positive predictive value of 72%, and an area under the receiver operating characteristic curve of 0.961. The predictive performance was similar for asymptomatic, weakly symptomatic and symptomatic participants and was not biased by the COVID-19 vaccination status.
Conclusions Real-time, non-invasive, artificial-intelligence-enhanced mass spectrometry breath analysis might be a reliable, safe, rapid, cost-effective, high-throughput method for COVID-19 screening.
Competing Interest Statement
S.G.D and C.R. are named as inventors on a patent application covering breath analysis in COVID-19 (WO 2022/058796, A method for analysing a breath sample for screening, diagnosis or monitoring of SARS-CoV-2 carriage or infection (COVID-19) on humans). The authors declare no other conflicts of interest.
Clinical Trial
EudraCT 2020-A02682-37 and EudraCT 2021-A00167-34
Funding Statement
This work was supported by Agence Nationale de la Recherche [COVINOse, ANR-21-CO12-0004]; Region Ile de France [VolatolHom, SESAME 2016]; and Fondation Foch.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The two study protocols were registered (VOC-COVID-Diag: EudraCT 2020-A02682-37; VOC-SARSCOV-Dep: EudraCT 2021-A00167-34) and approved by an independent ethics committee (CPP Nord-Ouest IV, 20.09.29.32837 and CPP Sud-Est II, 2021-017).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The study protocol and the datasets generated during and/or analysed during the current study, including deidentified participant data, will be available (after publication) from the corresponding author on reasonable request.
